Evidence map›Paper›PMID 38292518›Full record

ArticleNeurobiology of stress2024

A reverse translational study of PPAR-α agonist efficacy in human and rodent models relevant to alcohol use disorder.

Barbara J Mason, David Estey, Amanda Roberts, Giordano de Guglielmo, Olivier George, John Light, Mike Stoolmiller, Susan Quello, Michael Skinner, Farhad Shadan and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurobiology of stress, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Barbara J MasonPearson Center for Alcohol and Addiction Research, Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
David EsteyPearson Center for Alcohol and Addiction Research, Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
Amanda RobertsPearson Center for Alcohol and Addiction Research, Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
Giordano de GuglielmoPearson Center for Alcohol and Addiction Research, Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
Olivier GeorgePearson Center for Alcohol and Addiction Research, Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
John LightOregon Research Institute, Eugene, OR, USA.
Mike StoolmillerPearson Center for Alcohol and Addiction Research, Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
Susan QuelloPearson Center for Alcohol and Addiction Research, Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
Michael SkinnerPearson Center for Alcohol and Addiction Research, Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
Farhad ShadanPearson Center for Alcohol and Addiction Research, Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
Adnan BegovicPearson Center for Alcohol and Addiction Research, Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
Mark C KylePearson Center for Alcohol and Addiction Research, Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
R Adron HarrisDepartment of Neuroscience, University of Texas at Austin, Austin, TX, USA.
Pearson (United States) · USScripps Research Institute · USOregon Research Institute · USThe University of Texas at Austin · USUniversity of California, San Diego · US

Funding

Viral Vector CoreP60AA006420 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI AMANDA J ROBERTS · 2003 to 2026
$46.3M
Alcohol Vapor Self-Administration in RatsR01AA022977 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Olivier George · 2014 to 2026
$5.1M
Proof-of-Concept Human Laboratory Testing of Novel Drug Candidates Identified by INIA-NeuroImmuneU01AA025476 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI MASON, BARBARA J · 2017 to 2021
$2.6M
Neuronal ensembles of compulsive alcohol drinkingR01AA026081 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GEORGE, OLIVIER · 2017 to 2021
$2.0M
NIAAA NIH HHS P60 AA006420NIAAA NIH HHS R01 AA022977NIAAA NIH HHS R01 AA026081NIAAA NIH HHS U01 AA025476
6 · The paper itself

Abstract

Alcohol Use Disorder (AUD) is a chronic relapsing disorder affecting an estimated 283 million individuals worldwide, with substantial health and economic consequences. Peroxisome proliferator-activated receptors (PPARs), particularly PPAR-α and PPAR-γ, have shown promise in preclinical studies as potential therapeutic targets for AUD. In this human laboratory study, we aimed to translate preclinical findings on the PPAR-α agonist fenofibrate to a human population with current AUD. We hypothesized that, relative to placebo, fenofibrate at the highest FDA-approved dose of 145 mg/d would attenuate responsiveness to

Indexed as

Alcohol use disorderFenofibrateHuman laboratory studyMousePeroxisome proliferator-activated receptor-alphaRat

Identifiers

PMID38292518
PMCPMC10825428
OpenAlexW4390604528

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.